Risk of CIN2 Recurrence After LEEP
Yes, CIN2 can return after LEEP, with recurrence rates ranging from 1.5% to 6.1%, though the majority of patients (approximately 94-95%) are cured after the procedure. 1, 2
Recurrence Rates
The risk of recurrent CIN2+ after LEEP is relatively low but clinically significant:
- Overall recurrence rate: 6.1% in a large cohort of 4,369 patients over 5 years 1
- Residual disease: 3.4% detected at 3 months post-procedure 2
- Late recurrence: 1.5-2.2% developing after initial clearance 2, 3
- Overall cure rate: 93.3-95% after first LEEP 2, 3
Key Risk Factors for Recurrence
Highest Risk Factors
HPV persistence is the single most important predictor of recurrence across all studies:
- Persistent high-risk HPV infection increases recurrence risk 12-fold (HR 12.09) 1
- HPV testing has 98% negative predictive value for ruling out recurrent disease, superior to negative margins (91% NPV) or cytology alone (93% NPV) 4
- Same HPV genotype persistence before and after LEEP had 100% sensitivity for detecting recurrence 5
Specific high-risk HPV genotypes carry elevated risk:
- HPV-16: 3.6-fold increased risk of recurrence 5
- HPV-33: 2.6-fold increased risk 1
- HPV-18: significantly associated with recurrent CIN2-3 5
- HPV-52: 1.6-fold increased risk 1
Other Significant Risk Factors
Positive surgical margins increase recurrence risk 6.5-fold (HR 6.48) 1:
- Positive margins occurred in 11.2% of LEEP cases vs. 4.2% in laser conization 6
- Margin involvement is associated with 4.8% residual disease and 4.8% recurrence 3
Additional risk factors include:
- Smoking: 3.2-fold increased risk (HR 3.17) 1
- Immunosuppression: 2.0-fold increased risk (HR 1.96) 1
- Baseline CIN3 diagnosis: 3.8-fold increased risk compared to CIN2 (HR 3.80) 6
Recommended Follow-Up Strategy
HPV DNA testing at 6-12 months post-treatment is the preferred surveillance method per ASCCP guidelines 7, 4:
- If HPV negative or two consecutive negative cytologies: return to routine screening for at least 20 years 7
- If HPV positive or cytology shows ASC-US or greater: perform colposcopy with endocervical sampling 7
- Cytology with endocervical sampling at 4-6 months is preferred if margins are positive 7
Critical Pitfall to Avoid
Never perform repeat treatment or hysterectomy based solely on positive HPV testing without histologic confirmation of recurrent disease 7. HPV persistence alone, while a risk factor, does not mandate immediate re-treatment.
Clinical Implications
Women with HPV-16/18 persistence and high-grade cytology warrant closer surveillance given their substantially elevated recurrence risk 5, 8. The combination of persistent HPV-16 with high-grade cytology represents the highest-risk scenario for progression 8.
For women with negative HPV testing post-LEEP, the risk of recurrence is extremely low (1-2%), providing strong reassurance 4, 2. This makes HPV-based testing the most reliable method for post-treatment surveillance, outperforming both margin status assessment and cytology alone 4.